442 related articles for article (PubMed ID: 34742741)
1. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies.
Fleming SM; Davis A; Simons E
Neuropharmacology; 2022 Jan; 202():108870. PubMed ID: 34742741
[TBL] [Abstract][Full Text] [Related]
2. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
4. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
5. Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.
Zella MAS; Metzdorf J; Ostendorf F; Maass F; Muhlack S; Gold R; Haghikia A; Tönges L
Cells; 2019 Jan; 8(2):. PubMed ID: 30708997
[TBL] [Abstract][Full Text] [Related]
6. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
Galiano-Landeira J; Torra A; Vila M; Bové J
Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
[TBL] [Abstract][Full Text] [Related]
7. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
9. A deadly spread: cellular mechanisms of α-synuclein transfer.
Steiner JA; Angot E; Brundin P
Cell Death Differ; 2011 Sep; 18(9):1425-33. PubMed ID: 21566660
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of α-Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective.
Yi S; Wang L; Wang H; Ho MS; Zhang S
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499080
[TBL] [Abstract][Full Text] [Related]
11. Determinants of dopaminergic neuron loss in Parkinson's disease.
Surmeier DJ
FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
[TBL] [Abstract][Full Text] [Related]
12. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
13. [Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].
Xu F; Luo JH; Jin JH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 37(5):524-30. PubMed ID: 18925724
[TBL] [Abstract][Full Text] [Related]
14. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
[TBL] [Abstract][Full Text] [Related]
15. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's Disease: Exploring Different Animal Model Systems.
Khan E; Hasan I; Haque ME
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240432
[TBL] [Abstract][Full Text] [Related]
17. [Pathological mechanisms of Parkinson's disease].
Matsui H; Takahashi R
Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
[TBL] [Abstract][Full Text] [Related]
18. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.
Luk KC; Kehm V; Carroll J; Zhang B; O'Brien P; Trojanowski JQ; Lee VM
Science; 2012 Nov; 338(6109):949-53. PubMed ID: 23161999
[TBL] [Abstract][Full Text] [Related]
19. The Nigral Coup in Parkinson's Disease by α-Synuclein and Its Associated Rebels.
Sian-Hulsmann J; Riederer P
Cells; 2021 Mar; 10(3):. PubMed ID: 33803185
[TBL] [Abstract][Full Text] [Related]
20. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.
Ferrer I; Martinez A; Blanco R; Dalfó E; Carmona M
J Neural Transm (Vienna); 2011 May; 118(5):821-39. PubMed ID: 20862500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
